Get the Stockscreener App
1.50
0.67%
0.01
NanoViricides Inc stock is traded at $1.50, with a volume of 302.57K.
It is up +0.67% in the last 24 hours and up +52.64% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.49
Open:
$1.48
24h Volume:
302.57K
Relative Volume:
1.13
Market Cap:
$32.39M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-3.1146
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
+2.74%
1M Performance:
+52.64%
6M Performance:
+0.00%
1Y Performance:
+17.19%
1-Day Range:
$1.4166
$1.51
1-Week Range:
$1.3701
$1.6499
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.50 | 32.18M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NNVC stock up 17% today: What’s driving the rally? - MSN
TradingKey - TradingKey
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship - citybuzz -
Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides… - Proactive financial news
NanoViricides says hantavirus incident highlights need for antiviral drugs - TipRanks
Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387 - Kavout
Cruise ship hantavirus deaths spark call for broad-spectrum antiviral drugs - Stock Titan
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - Proactive financial news
What NanoViricides (NNVC) bond yields suggest about risk | Q1 2026: Earnings Beat EstimatesWall Street Picks - newser.com
NNVC (NanoViricides) shares surge 9% as EPS beat targets by 23%, defying analyst expectations despite ongoing losses.Trading Community - newser.com
NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials - citybuzz -
NanoViricides to Present at D. Boral Capital Global Conference - HarianBasis.co
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - Insider Monkey
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - Yahoo Finance
NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC - Pluang
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - MEXC Exchange
NanoViricdes Surges on Winning ODD Status - Baystreet.ca
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - Lelezard
NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment - Yahoo Finance
FDA orphan tag gives NanoViricides measles drug tax credits, fee waiver - Stock Titan
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Is NanoViricides (NNVC) stock forming a clear pattern | Q1 2026: Profit Exceeds ViewsShared Buy Zones - newser.com
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC (NanoViricides Inc.) beats Q1 2026 EPS estimates by 23 percent, but posts a slight post-earnings share decline. - Cổng thông tin điện tử tỉnh Tây Ninh
NNVC NanoViricides exceeds Q1 2026 EPS estimates by 23 percent, but shares drop 4.89 percent on zero quarterly revenue.Trading Community - UBND thành phố Hải Phòng
NanoViricides says NV-387 could address measles outbreaks as cases rise globally - Yahoo Finance
Deadly Measles Cases Accentuate the Need for a - One News Page
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
Can NanoViricides (NNVC) Stock Go Higher | Price at $1.15, Up 6.48%Trade Entry - newser.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):